Dr Alfredo Pavlovsky, a doctor in Buenos Aires, Argentina, distinguishes two types of haemophilia in his lab – A and B.1
Stephen Christmas is diagnosed with haemophilia B, which doctors colloquially refer to as Christmas Disease. Fresh frozen plasma is the only treatment option available, and the average life expectancy is less than 20 years old.1
Stephen Christmas is diagnosed with haemophilia B, which doctors colloquially refer to as Christmas Disease. Fresh frozen plasma is the only treatment option available, and the average life expectancy is less than 20 years old.1
Dan has experienced the full treatment spectrum for haemophilia, from lyophilised plasma to factor. Now with a young grandson who also has haemophilia, he’s amazed by how far we’ve come and is excited for where the science is headed.
Dan's storyFactor concentrates in powdered form become available, allowing for home infusions and a significant reduction in treatment time.1
Researchers pioneer genetic engineering, creating the potential to treat genetic conditions by modifying a person’s genes.2
Factor concentrates in powdered form become available, allowing for home infusions and a significant reduction in treatment time.1
Researchers pioneer genetic engineering, creating the potential to treat genetic conditions by modifying a person’s genes.2
Sue
Sue, a now-retired nurse coordinator, spent the last three decades on the front lines caring for people with haemophilia.
Sue's storyScientists successfully clone the Factor VIII and IX genes, paving the way for breakthrough synthetic therapies (not derived from human plasma) using recombinant technologies.1
Scientists successfully clone the Factor VIII and IX genes, paving the way for breakthrough synthetic therapies (not derived from human plasma) using recombinant technologies.1
The first recombinant FIX products are approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) to treat haemophilia B, leading the way for prophylactic treatment, which dramatically improves patients’ lives.1,3
Haemophilia patient life expectancy improves to 67 years old.4
The first recombinant FIX products are approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) to treat haemophilia B, leading the way for prophylactic treatment, which dramatically improves patients’ lives.1,3
Haemophilia patient life expectancy improves to 67 years old.4
Adam
A child of the 90s, Adam felt comfortable engaging in most activities with family and friends thanks to the availability of prophylactic haemophilia treatments.
Adam's StoryDr. Klamroth
A leader in the haemophilia medical community, Dr. Klamroth has witnessed several major treatment advancements over the past 25 years and looks forward to what the next 25 years will bring.
Dr. Klamroth’s StoryEvidence grows for the potential of adeno-associated virus (AAV) vectors to deliver safe, effective, and lasting genes that produce blood-clotting factor in the body.1
Evidence grows for the potential of adeno-associated virus (AAV) vectors to deliver safe, effective, and lasting genes that produce blood-clotting factor in the body.1
Jeron
Though held back from playing sports as a child, Jeron has channelled his energy into being an advocate in the haemophilia community, travelling the world and inspiring others with the condition.
Jeron's StoryLong-acting recombinant factor therapies are available offering the haemophilia community additional treatment options.1
Late-stage trials for AAV-based gene therapy in haemophilia begin.6
Long-acting recombinant factor therapies are available offering the haemophilia community additional treatment options.1
Late-stage trials for AAV-based gene therapy in haemophilia begin.6
Stormy
As a woman with haemophilia and a caregiver to a son with haemophilia, Stormy has made it her mission to educate others, advocating for men and women alike in the haemophilia community.
Stormy's story
Gene therapy trials in haemophilia continue to show promise in potentially decreasing annualised bleeding rates as well as the use of replacement therapy.8
Gene therapy trials in haemophilia continue to show promise in potentially decreasing annualised bleeding rates as well as the use of replacement therapy.8
Wayne
As an advocate for haemophilia for over 40 years, Wayne has experienced monumental advancements in haemophilia treatments and has committed his life to ensuring a better world for today’s haemophilia community.
Wayne's storyLukas
Diagnosed at nine months old, Lukas hopes to shine a light on life with haemophilia, including the importance of increasing understanding of the disease to ensure children with haemophilia are given the same opportunities as their peers at school, as well as his hopes for the future.
Lukas' storyAlex and Josh
Alex and Josh, now 26, were born and raised in the UK. At three years old the brothers were diagnosed with severe haemophilia A. Growing up they found it difficult to fit in with their peers, especially as they were unable to take part in popular school sports such as rugby. Despite this, they got used to learning how to better manage their haemophilia and now strive to live as ‘normal’ a life as possible.
Alex and Josh's story
Fabio
Fabio is 27 years old and was diagnosed with severe haemophilia B when he was two. Despite the setbacks he has faced, Fabio does not allow haemophilia to hinder his passions. He actively participates in sports, cycling around his hometown of Zaragoza, Spain and camping in the mountains. Hopes for new treatment options keep Fabio optimistic for the future, with the prospect of a freer life, away from regular hospital visits.
Fabios' story
Eke and Sterre
Eke and Sterre, a mother and daughter with haemophilia, share their experiences, emphasising the advances made in the understanding and treatment of haemophilia in women and girls.
Eke and Sterre's story